JP2013512277A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512277A5
JP2013512277A5 JP2012542076A JP2012542076A JP2013512277A5 JP 2013512277 A5 JP2013512277 A5 JP 2013512277A5 JP 2012542076 A JP2012542076 A JP 2012542076A JP 2012542076 A JP2012542076 A JP 2012542076A JP 2013512277 A5 JP2013512277 A5 JP 2013512277A5
Authority
JP
Japan
Prior art keywords
compound
salt
pharmaceutically acceptable
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542076A
Other languages
English (en)
Japanese (ja)
Other versions
JP5709889B2 (ja
JP2013512277A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057359 external-priority patent/WO2011066183A1/en
Publication of JP2013512277A publication Critical patent/JP2013512277A/ja
Publication of JP2013512277A5 publication Critical patent/JP2013512277A5/ja
Application granted granted Critical
Publication of JP5709889B2 publication Critical patent/JP5709889B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542076A 2009-11-30 2010-11-19 新規スピロピペリジン化合物 Expired - Fee Related JP5709889B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26518109P 2009-11-30 2009-11-30
US61/265,181 2009-11-30
PCT/US2010/057359 WO2011066183A1 (en) 2009-11-30 2010-11-19 Novel spiropiperidine compounds

Publications (3)

Publication Number Publication Date
JP2013512277A JP2013512277A (ja) 2013-04-11
JP2013512277A5 true JP2013512277A5 (OSRAM) 2013-11-14
JP5709889B2 JP5709889B2 (ja) 2015-04-30

Family

ID=43384775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542076A Expired - Fee Related JP5709889B2 (ja) 2009-11-30 2010-11-19 新規スピロピペリジン化合物

Country Status (26)

Country Link
US (1) US8822486B2 (OSRAM)
EP (1) EP2507228B1 (OSRAM)
JP (1) JP5709889B2 (OSRAM)
KR (1) KR101410103B1 (OSRAM)
CN (1) CN102648195B (OSRAM)
AR (1) AR078948A1 (OSRAM)
AU (1) AU2010324987B2 (OSRAM)
BR (1) BR112012012903A2 (OSRAM)
CA (1) CA2781292C (OSRAM)
CL (1) CL2012001321A1 (OSRAM)
CR (1) CR20120296A (OSRAM)
DO (1) DOP2012000139A (OSRAM)
EA (1) EA020507B1 (OSRAM)
EC (1) ECSP12011930A (OSRAM)
ES (1) ES2526568T3 (OSRAM)
GT (1) GT201200164A (OSRAM)
IL (1) IL219594A0 (OSRAM)
MA (1) MA33840B1 (OSRAM)
MX (1) MX2012006233A (OSRAM)
NZ (1) NZ600203A (OSRAM)
PE (1) PE20121474A1 (OSRAM)
PH (1) PH12012501052A1 (OSRAM)
TN (1) TN2012000248A1 (OSRAM)
TW (1) TW201141866A (OSRAM)
WO (1) WO2011066183A1 (OSRAM)
ZA (1) ZA201203055B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
RU2567755C2 (ru) 2009-12-25 2015-11-10 Мотида Фармасьютикал Ко., Лтд. Новое производное 3-гидрокси-5-арилизотиазола
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US8557766B2 (en) 2011-04-27 2013-10-15 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
WO2012147516A1 (ja) 2011-04-28 2012-11-01 持田製薬株式会社 環状アミド誘導体
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2014159054A1 (en) 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
EA201690888A1 (ru) 2013-11-14 2016-10-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
MY196582A (en) 2018-02-13 2023-04-19 Gilead Sciences Inc PD-1/PD-L1 Inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
JP7745559B2 (ja) 2020-02-28 2025-09-29 キャリーオペ,インク. Gpr40アゴニスト
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ,インク. Ampkアクチベーター

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
BRPI0409078A (pt) 2003-04-04 2006-04-18 Merck & Co Inc composto, métodos para o tratamento ou prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, para o tratamento ou prevenção de obesidade, para o tratamento ou prevenção de um distúrbio relacionado com a obesidade, para o tratamento ou prevenção de diabete melito, para o tratamento ou prevenção da disfunção sexual masculina ou feminina e para o tratamento ou prevenção de disfunção erétil, composição farmacêutica, métodos para o tratamento de disfução erétil em um mamìfero, para o tratamento de diabete em um mamìfero e para o tratamento de obesidade em um mamìfero, e, uso de um composto
WO2005046682A1 (en) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
KR20070004769A (ko) 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
ATE429426T1 (de) * 2004-09-07 2009-05-15 Banyu Pharma Co Ltd Carbamoylsubstituiertes spiro-derivat
AU2007275931B2 (en) * 2006-07-19 2011-06-16 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
EP2125827B1 (en) * 2006-12-29 2010-11-03 F. Hoffmann-La Roche AG Azaspiro derivatives
CA2683751C (en) * 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
EP2202216B1 (en) * 2007-10-26 2012-06-27 Japan Tobacco Inc. Spiro-ring compound and use thereof for medical purposes
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Similar Documents

Publication Publication Date Title
JP2013512277A5 (OSRAM)
JP2013508279A5 (OSRAM)
JP2012526728A5 (OSRAM)
JP2016503799A5 (OSRAM)
JP2013507423A5 (OSRAM)
JP2014500861A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2007302689A5 (OSRAM)
JP2013518107A5 (OSRAM)
JP2015500843A5 (OSRAM)
JP2016530259A5 (OSRAM)
JP2016006118A5 (OSRAM)
JP2013032389A5 (OSRAM)
JP2009523760A5 (OSRAM)
JP2013503846A5 (OSRAM)
JP2012512863A5 (OSRAM)
JP2014530900A5 (OSRAM)
JP2013542261A5 (OSRAM)
JP2010077141A5 (OSRAM)
JP2013510123A5 (OSRAM)
JP2006524660A5 (OSRAM)
JP2011504903A5 (OSRAM)
JP2014516033A5 (OSRAM)
JP2011500658A5 (OSRAM)
JP2011518833A5 (OSRAM)